A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability

B. ten Cate, E. Bremer, M. de Bruyn, T. Bijma, D. Samplonius, M. Schwemmlein, G. Huls, G. Fey, W. Helfrich*

*Corresponding author voor dit werk

Onderzoeksoutput › Academic › peer review

60 Citaten (Scopus)

Vingerafdruk

Duik in de onderzoeksthema's van 'A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability'. Samen vormen ze een unieke vingerafdruk.

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases